Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
40.92 USD | +0.05% | -4.81% | -14.39% |
May. 03 | Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $47 From $48, Keeps Neutral Rating | MT |
May. 02 | Transcript : Ultragenyx Pharmaceutical Inc., Q1 2024 Earnings Call, May 02, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.39% | 3.4B | |
+5.69% | 109B | |
+11.09% | 105B | |
-0.38% | 22.25B | |
-12.11% | 22.09B | |
-7.66% | 18.68B | |
-36.52% | 17.58B | |
-10.30% | 16.85B | |
+2.96% | 13.76B | |
+35.95% | 12.46B |
- Stock Market
- Equities
- RARE Stock
- News Ultragenyx Pharmaceutical Inc.
- Ultragenyx Pharmaceutical Chief Financial Officer Mardi Dier to Depart for Private Biopharma Company